Clinical Trial

Machine Learning for Predicting and Managing Quality of Life in Lung Cancer Immunotherapy Patients

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 13, 2024 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to explore whether health-related quality of life (HRQoL) can be used as a predictive indicator for lung cancer patients and to implement clinical interventions. The study addresses two main objectives: Analyzing HRQoL data of lung cancer patients undergoing immunotherapy using machine learning clustering methods to explore data patterns and build an HRQoL early warning model (already developed). Validating this HRQoL early warning model in real-world settings by classifying patients with different HRQoL characteristics and assessing the clinical value of the model
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-07.
Trial Details
NCT Number NCT06725225
Lead Sponsor Second Affiliated Hospital of Zunyi Medical University
Collaborators: Ministry of Education of the People's Republic of China, Department of Humanities and Social Sciences
Conditions Lung Cancer Patients
Enrollment 200 participants
Start Date 2025-01-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-12-13